Nuvation Bio Inc (NYSE: NUVB) kicked off on Tuesday, up 2.74% from the previous trading day, before settling in for the closing price of $5.85. Over the past 52 weeks, NUVB has traded in a range of $1.54-$9.75.
Annual sales at Healthcare sector company slipped by -49.14% over the past five years. While this was happening, its average annual earnings per share was recorded 72.18%. With a float of $239.39 million, this company’s outstanding shares have now reached $341.76 million.
Nuvation Bio Inc (NUVB) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nuvation Bio Inc is 30.38%, while institutional ownership is 53.84%. The most recent insider transaction that took place on Dec 01 ’25, was worth 1,173,255. In this transaction CHIEF MEDICAL OFFICER of this company sold 150,000 shares at a rate of $7.82, taking the stock ownership to the 18,000 shares. Before that another transaction happened on Dec 01 ’25, when Company’s Officer proposed sale 150,000 for $7.82, making the entire transaction worth $1,173,255.
Nuvation Bio Inc (NUVB) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.12 earnings per share (EPS), higher than consensus estimate (set at -0.12) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 72.18% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 63.43% during the next five years compared to -49.14% drop over the previous five years of trading.
Nuvation Bio Inc (NYSE: NUVB) Trading Performance Indicators
Take a look at Nuvation Bio Inc’s (NUVB) current performance indicators. Last quarter, stock had a quick ratio of 8.39. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 77.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.64, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.41 in one year’s time.
